The patient was a 70-year-old male whose chief complaints were obstructive jaundice and weight loss. Abdominal imaging studies showed a 2.5 cm sized mass at the distal common bile duct, which was suggestive of bile duct cancer. Eccentric enhancing wall thickening in the transverse colon was also shown, suggesting concomitant colon cancer. A colonoscopy revealed a lumen-encircling ulcerofungating mass in the transverse colon, that was pathologically proven to be adenocarcinoma. The bile duct pathology was also adenocarcinoma. Pylorus-preserving pancreaticoduodenectomy and extended right hemicolectomy were performed under the diagnosis of double primary cancers. Postoperative histopathologic examination revealed moderately differentiated mucinous adenocarcinoma of transverse colon cancer, and mucinous adenocarcinoma of the distal common bile duct. Immunohistochemical staining studies showed that the bile duct cancer had metastasized from the colon cancer. The patient recovered uneventfully from surgery and will be undergoing chemotherapy for three months. 
INTRODUCTION
Malignant extrahepatic bile duct obstruction is mostly caused by primary bile duct cancer, or via the metastasis of other tumors to the peripancreatic, periportal, peribiliary lymph nodes, and the head of the pancreas. 1 The primary cancers that cause metastatic biliary obstruction include carcinomas from the stomach, colon, lung, uterus, and breast. Among them, common malignant tumors that could cause metastatic extrahepatic bile duct obstruction are stomach cancer and colon cancer; 2,3 however, biliary obstruction associated with metastatic mucinous adenocarcinoma of the colon to the distal common bile duct is even rarer in non-biliary cancers. Moreover, colonic mucinous adenocarcinoma is relatively rare, accounting for less than 5% of colorectal cancers; when it is diagnosed at an advanced stage, the prognosis is worse. 4 In the literature review, there is no report regarding metastatic mucinous adenocarcinoma of the distal common bile duct from colon cancer-thus, we present a sample case of this disease.
CASE
A 70-year-old man presented with obstructive jaundice and weight loss, for two weeks. He did not have a history of hypertension, diabetes mellitus, tuberculosis and liver disease. Upon a physical examination, the patient did not appear to be so ill-looking, and showed icteric sclera. A laboratory evaluation revealed obstructive jaundice with a total bilirubin of 5.4 mg/dl, alkaline phosphatase of 640 IU/L, aspartate aminotransferase of 573 IU/L, and alanine aminotransferase of 841 IU/L. The carcinoembryonic antigen (CEA) was 2.4 ng/ml, the alpha-fetoprotein was 3.05 (+), cytokeratin 20 (+), CDX2 (+), and p53 (-), by which we concluded that the bile duct cancer had metastasized from colon cancer (Fig. 4) . The patient recovered uneventfully from surgery, and will be undergoing adjuvant systemic chemotherapy for three months.
DISCUSSION
Patients with primary bile duct cancers typically present with painless jaundice resulting from the perihilar or distal biliary strictures, or with an intrahepatic mass, causing abdominal pain. Common non-biliary malignancies that can cause distal biliary obstruction are: stomach cancer, colon cancer and breast cancer; 2 however, biliary obstruction caused by mucinous adenocarcinoma of the colon is rare, and is mostly due to the compression of the bile duct by metastasis to the surrounding the lymph nodes, or to the pancreas head.
The most frequent site of metastatic malignant biliary obstruction is the common bile duct, at the level of the cystic duct. 5 In general, metastatic lymphadenopathy in the hepatoduodenal ligament is the main cause of biliary obstruction. 6 According to some reports, however, the hepatic hilum was the most common level of obstruction. 7, 8 Moon et al. reported that the proximal common bile duct (20/50, 40%) and hilum (18/50, 36%) were the most frequent levels of biliary obstruction, followed by the periampullary area (14%) and the distal common bile duct (10%), because of biliary obstruction in metastatic cancer. When an intraductal lesion was detected on the CT images of a patient with extra-biliary neoplasm, the following findings were found to be suggestive of intraductal metastasis, rather than intraductal cholangiocarcinoma:
colorectal cancer as the extra-biliary malignant disease, a parenchymal mass that was contiguous with the intraductal lesion, and expansile growth of the intraductal lesion. 3 The significant point that differentiates intraductal metastasis from intraductal cholangiocarcinoma was the morphologic features of the intraductal lesion. The appearance of the intraductal lesion in pathologic specimens differed for intraductal metastasis and intraductal cholangiocarcinoma, which contributed to the differences in the diagnostic imaging features. 9 In the intraluminal extension, the tumor grows in the ductal lumen as papillary projections, resembling tumor thrombi. However, in the intraepithelial extension, the cancer cells advance along the intact basement membranes and replace the non-neoplastic biliary ductal epithelium. Usually, intraductal metastasis exhibits expansile intraluminal extension, but intraductal cholangiocarcinoma exhibits intraepithelial extension with a papillary growth pattern, due to its origination from the underlying papilloma or adenoma. 10 We performed immunohistochemical staining studies, as an additional tool for the differentiation of intraductal metastasis and intraductal cholangiocarcinoma. The immunohistochemical reaction to cytokeratin, such as cytokeratin 7 and cytokeratin 20, is well known to enhance the diagnosis. 9 The colorectal epithelium is immunoreactive to the anticytokeratin 20 antibody, but not to anticytokeratin 7 antibody, which is reactive to biliary epithelium. Therefore, a cytokeratin 20-positive and cytokeratin 7-negative immunohistochemical staining pattern is a characteristic of biliary metastasis from colorectal cancer. 11 Cytokeratin 19 is normally expressed in the lining of the gastropancreatic and hepatobiliary tracts, which is positive in most adenocarcinomas in the gastrointestinal tract and pancreas. 12 The expression of CDX2 in adults is restricted to the intestine, from the duodenum to the rectum. CDX2 is regarded as a specific marker of the intestinal epithelial cells, that can be utilized for identifying the colorectal origin of metastatic adenocarcinomas. 13 p53
is a tumor suppressor gene that is located on the short arm of chromosome 17, and the p53 mutation is required for the development of colorectal cancer, and is associated with an increased relative risk of death, and poorer prognosis.
